<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Intravenous brain-derived neurotrophic factor (BDNF) causes a 65-70% reduction in <z:hpo ids='HP_0001297'>stroke</z:hpo> volume in rats with the middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO), provided the BDNF is conjugated to a blood-brain barrier (<z:chebi fb="2" ids="33602">BBB</z:chebi>) molecular Trojan horse </plain></SENT>
<SENT sid="1" pm="."><plain>The latter may be a peptidomimetic monoclonal antibody (MAb) to the transferrin receptor </plain></SENT>
<SENT sid="2" pm="."><plain>The present studies determine whether the effects on <z:hpo ids='HP_0001297'>stroke</z:hpo> volume correlate with an improvement in neuro-behavior using the rotarod test </plain></SENT>
<SENT sid="3" pm="."><plain>The rotarod latency was &gt;200 s at 16 RPM in <z:hpo ids='HP_0000001'>all</z:hpo> rats pre-MCAO </plain></SENT>
<SENT sid="4" pm="."><plain>The latency was 30+/-7 s and 103+/-9 s at 24 h post-MCAO in the animals treated with BDNF alone and the BDNF-MAb conjugate, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>These studies show that when BDNF is formulated to enable transport across the <z:chebi fb="2" ids="33602">BBB</z:chebi>, the intravenous administration of the neurotrophin results in a reduction in <z:hpo ids='HP_0001297'>stroke</z:hpo> volume that is associated with a parallel improvement in functional outcome </plain></SENT>
</text></document>